ArticleScientific reports2020
Controlling evolution of protein corona: a prosperous approach to improve chitosan-based nanoparticle biodistribution and half-life.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 115 citations in OpenAlex.
- CO-mediated restoration of mitochondrial redox homeostasis contributes to alleviating multiple programmed cell deaths in hepatic I/R injury.Redox biology · 2026Article
- Nanoparticle Behavior in the Body: Biochemical, Pharmacological and Cellular Aspects.Nanomaterials (Basel, Switzerland) · 2026Review
- Biologically Mediated Nanoparticle Synthesis as a Potential Green Strategy: Principles, Methods, and Pharmaceutical Applications.Pharmaceutics · 2026Review
- pH responsive nanoplatforms for radiosensitization and radioprotection in cancer therapy.Discover oncology · 2026Review
- Layer by Layer Engineered Lipid-Based Nanocarriers for Therapeutic Delivery and Next-Generation Design.Pharmaceutics · 2026Review
- The Impact of Biomaterial Charge on Cells' Bioelectrical Signaling.Cells, tissues, organs · 2026Review
- The protein corona at the nano-bio interface: the need for standardized methodology and opportunities for neurodegenerative disease intervention.RSC advances · 2026Review
- A physics-informed machine learning framework for predicting and mitigating doxorubicin nanocarrier toxicity in normal cells.Scientific reports · 2026Article
- Advancing the Landscape of RNAi Nanotherapeutics for Ischemic Heart Disease.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Hepatocyte-Targeted Drug Delivery Strategies for Chronic Hepatitis B: Overcoming Delivery Barriers Toward Functional Cure.Pharmaceutics · 2026Review
- Orthogonal Investigation at Single-Particle and Ensemble Levels Uncovers Lipoprotein-Extracellular Vesicle Binding.Analytical chemistry · 2026Article
- Disease modifying biomaterials for modulating mechanical allodynia in a preclinical model of rheumatoid arthritis.Bioengineering & translational medicine · 2025Article
- Activation of the coagulation cascade as a mechanism for selective nanoparticle-mediated RNA delivery to the endothelium in vivo.Science advances · 2025Article
- CHIVAX 2.1-Loaded Chitosan Nanoparticles as Intranasal Vaccine Candidates for COVID-19: Development and Murine Safety Assessment.Biomedicines · 2025Article
- Advances in controlled release drug delivery systems based on nanomaterials in lung cancer therapy: A review.Medicine · 2025Review
- How do nanoparticle properties shape pharmacokinetics and pharmacodynamics? A mechanistic review.Frontiers in pharmacology · 2025Review
- Protein Binding Leads to Reduced Stability and Solvated Disorder in the Polystyrene Nanoparticle Corona.Small (Weinheim an der Bergstrasse, Germany) · 2024Article
- Revolutionizing Cardiovascular Health with Nano Encapsulated Omega-3 Fatty Acids: A Nano-Solution Approach.Marine drugs · 2024Review
- Targeted Thrombolysis with Magnetic Nanotherapeutics: A Translational Assessment.Pharmaceutics · 2024Article
- Lipidomics Analysis Unravels Aberrant Lipid Species and Pathways Induced by Zinc Oxide Nanoparticles in Kidney Cells.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein corona significantly affects in vivo fate of nanoparticles including biodistribution and half-life. Without manipulating the physicochemical properties of nanoparticles with considering their biointerference, attaining effective treatment protocols is impossible. For this reason, protein corona evolution and biodistribution of different chitosan (Ch)-based nanoparticles including Ch and carboxymethyl dextran (CMD)/thiolated dextran (TD) polyelectrolyte complexes (PECs) were studied using highly precious and sensitive methods such as liquid chromatography-mass/mass (LC-MS/MS) spectroscopy and positron emission tomography/computed tomography (PET/CT) scan. The importance of serum presence/absence in culture medium with different pH and corona effect on cellular uptake of PECs investigated by in vitro study. Designed PECs have low amounts of proteins in corona mostly enriched by Apolipoproteins, protein C, hemoglobin subunits, and inter-alpha- trypsin inhibitor that beside improving uptake of nanoparticles, they have low liver uptake and notable heart blood pool accumulation that confirmed the long circulation time of the nanoparticles which is favorable for delivery of nanoparticles to the site of action and achieving required therapeutic effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.